HER2-Positive Breast Cancer Global Market Report 2025

Description

HER2-positive breast cancer is a form of breast cancer distinguished by an excess of the human epidermal growth factor receptor 2 (HER2) protein. This protein accelerates the growth of cancer cells and is present in about 15-20% of breast cancer cases. Generally, HER2-positive breast cancer tends to be more aggressive compared to HER2-negative types but can be treated using targeted therapies that block HER2 activity.

The primary treatment options for HER2-positive breast cancer include targeted therapy, chemotherapy, endocrine therapy, immunotherapy, and other methods. Targeted therapy is a treatment that specifically targets certain molecules, such as proteins or genes that drive cancer growth, while minimizing damage to healthy cells. These medications can be administered through different methods, including intravenous, oral, and other routes. They are distributed through various outlets such as hospital pharmacies, retail pharmacies, and online platforms, and are utilized by different end users such as hospitals, home care services, specialty clinics, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The HER2-positive breast cancer market research report is one of a series of new reports from The Business Research Company that provides HER2- positive breast cancer market statistics, including the HER2- positive breast cancer industry global market size, regional shares, competitors with the HER2- positive breast cancer market share, detailed HER2- positive breast cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the HER2- positive breast cancer industry. This HER2- positive breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The her2-positive breast cancer market size has grown strongly in recent years. It will grow from $10.21 billion in 2024 to $10.93 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increasing early detection and diagnosis, rising awareness of HER2-positive subtypes, growing investments in research and development, rising adoption of precision medicine, and growing focus on improving patient outcomes.

The her2-positive breast cancer market size is expected to see strong growth in the next few years. It will grow to $14.3 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising demand for liquid biopsy for non-invasive monitoring, rising adoption of combination treatments, growing focus on immunotherapies and novel drug formulations, increasing use of liquid biopsy techniques for non-invasive monitoring, and increasing number of specialized cancer treatment centers. Major trends in the forecast period include advancements in targeted therapies, novel formulations, innovations in immunotherapy approaches, the development of novel HER2-targeted therapies, and advancements in biomarkers for better patient stratification.

The forecast of 6.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. cancer care by increasing costs for trastuzumab biosimilars and pertuzumab imported from South Korea and Switzerland, potentially leading to treatment rationing and higher out-of-pocket costs for patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing adoption of immunotherapy is expected to drive significant growth in the HER2-positive breast cancer market. Immunotherapy is a treatment that boosts or modifies the immune system's natural ability to fight diseases, including cancer. It works by enhancing the immune system's capacity to identify and eliminate cancer cells, offering improved efficacy and fewer side effects compared to traditional treatments. For HER2-positive breast cancer, immunotherapy helps by enabling the body's immune system to target and attack HER2-overexpressing cancer cells, improving patient outcomes and reducing the risk of recurrence. According to the American Association for Cancer Research, in 2023, the FDA approved 11 immune checkpoint inhibitors (ICIs), with at least one authorized for the treatment of 20 different cancer types and for any solid tumor with specific molecular markers. This strong adoption of immunotherapy is helping to expand the HER2-positive breast cancer market.

Companies in the HER2-positive breast cancer market are focused on developing innovative therapies to improve treatment efficacy and patient outcomes. One such therapy is HER2-directed antibody-drug conjugates (ADCs), which combine antibodies targeting HER2 with cytotoxic drugs, delivering the drug directly to HER2-positive cancer cells for more precise and effective treatment. For example, in January 2024, AstraZeneca India Pharma Ltd. launched Trastuzumab deruxtecan, a HER2-directed ADC developed in collaboration with Daiichi Sankyo. Trastuzumab deruxtecan targets HER2-positive cancer cells and delivers a cytotoxic drug directly to the site, offering a more targeted approach to treatment.

In May 2023, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired the rights to Zion Pharma's lead program, ZN-A-1041, for an undisclosed amount. This acquisition aims to accelerate the development and commercialization of ZN-A-1041, a blood-brain-barrier-penetrant HER2 inhibitor designed to treat brain metastases in HER2-positive breast cancer patients. Zion Pharma, based in China, specializes in developing drugs for HER2-positive breast cancer, and this collaboration with Roche focuses on advancing treatment options for patients with brain metastases, a common complication in HER2-positive breast cancer.

Major players in the her2-positive breast cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.

North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in HER2- positive breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the HER2- positive breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The HER2-positive breast cancer market consists of sales of small molecule inhibitors, antibody-drug conjugates, and monoclonal antibodies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

HER2-Positive Breast Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on her2-positive breast cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for her2-positive breast cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The her2-positive breast cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Type: Targeted Therapy; Chemotherapy; Endocrine Therapy; Immunotherapy; Other Treatment Types
2) By Route Of Administration: Parenteral; Oral; Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End User
Subsegments:
1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab); Tyrosine Kinase Inhibitors (TKIs); Antibody-Drug Conjugates (ADC); Small Molecule Inhibitors
2) By Chemotherapy: Anthracycline-based Chemotherapy; Taxane-based Chemotherapy; Platinum-based Chemotherapy; Combination Chemotherapy Regimens
3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Estrogen Receptor Antagonists; Estrogen Deprivation Therapy
4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors); Monoclonal Antibodies for Immune Modulation; Cancer Vaccines
5) By Other Treatment Types: Radiation Therapy; Stem Cell Therapy; Hyperthermia Treatment; Gene Therapy; Surgical Interventions (Mastectomy, Breast Conserving Surgery)
Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.; AstraZeneca plc; Novartis International AG; GlaxoSmithKline plc; Eli Lilly and Company; Amgen Inc.; Boehringer Ingelheim GmbH; Daiichi Sankyo Co. Ltd.; Incyte Corporation; BioNTech SE; MacroGenics Inc.; CStone Pharmaceuticals Co. Ltd.; Sorrento Therapeutics Inc.; Syndax Pharmaceuticals Inc.; Fate Therapeutics Inc.; Ambrx Biopharma Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r33762u

1. Executive Summary

2. HER2-Positive Breast Cancer Market Characteristics

3. HER2-Positive Breast Cancer Market Trends And Strategies

4. HER2-Positive Breast Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global HER2-Positive Breast Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global HER2-Positive Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global HER2-Positive Breast Cancer Market Growth Rate Analysis
5.4. Global HER2-Positive Breast Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global HER2-Positive Breast Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global HER2-Positive Breast Cancer Total Addressable Market (TAM)

6. HER2-Positive Breast Cancer Market Segmentation

6.1. Global HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Chemotherapy
Endocrine Therapy
Immunotherapy
Other Treatment Types
6.2. Global HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Parenteral
Oral
Other Route Of Administrations
6.3. Global HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global HER2-Positive Breast Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End User
6.5. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
HER2 Inhibitors (Trastuzumab, Pertuzumab)
Tyrosine Kinase Inhibitors (TKIs)
Antibody-Drug Conjugates (ADC)
Small Molecule Inhibitors
6.6. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anthracycline-based Chemotherapy
Taxane-based Chemotherapy
Platinum-based Chemotherapy
Combination Chemotherapy Regimens
6.7. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Endocrine Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective Estrogen Receptor Modulators (SERMs)
Aromatase Inhibitors
Estrogen Receptor Antagonists
Estrogen Deprivation Therapy
6.8. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors)
Monoclonal Antibodies for Immune Modulation
Cancer Vaccines
6.9. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Radiation Therapy
Stem Cell Therapy
Hyperthermia Treatment
Gene Therapy
Surgical Interventions (Mastectomy, Breast Conserving Surgery)

7. HER2-Positive Breast Cancer Market Regional And Country Analysis

7.1. Global HER2-Positive Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global HER2-Positive Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific HER2-Positive Breast Cancer Market

8.1. Asia-Pacific HER2-Positive Breast Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China HER2-Positive Breast Cancer Market

9.1. China HER2-Positive Breast Cancer Market Overview
9.2. China HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India HER2-Positive Breast Cancer Market

10.1. India HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan HER2-Positive Breast Cancer Market

11.1. Japan HER2-Positive Breast Cancer Market Overview
11.2. Japan HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia HER2-Positive Breast Cancer Market

12.1. Australia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia HER2-Positive Breast Cancer Market

13.1. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea HER2-Positive Breast Cancer Market

14.1. South Korea HER2-Positive Breast Cancer Market Overview
14.2. South Korea HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe HER2-Positive Breast Cancer Market

15.1. Western Europe HER2-Positive Breast Cancer Market Overview
15.2. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK HER2-Positive Breast Cancer Market

16.1. UK HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany HER2-Positive Breast Cancer Market

17.1. Germany HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France HER2-Positive Breast Cancer Market

18.1. France HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy HER2-Positive Breast Cancer Market

19.1. Italy HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain HER2-Positive Breast Cancer Market

20.1. Spain HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe HER2-Positive Breast Cancer Market

21.1. Eastern Europe HER2-Positive Breast Cancer Market Overview
21.2. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia HER2-Positive Breast Cancer Market

22.1. Russia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America HER2-Positive Breast Cancer Market

23.1. North America HER2-Positive Breast Cancer Market Overview
23.2. North America HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA HER2-Positive Breast Cancer Market

24.1. USA HER2-Positive Breast Cancer Market Overview
24.2. USA HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada HER2-Positive Breast Cancer Market

25.1. Canada HER2-Positive Breast Cancer Market Overview
25.2. Canada HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America HER2-Positive Breast Cancer Market

26.1. South America HER2-Positive Breast Cancer Market Overview
26.2. South America HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil HER2-Positive Breast Cancer Market

27.1. Brazil HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East HER2-Positive Breast Cancer Market

28.1. Middle East HER2-Positive Breast Cancer Market Overview
28.2. Middle East HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa HER2-Positive Breast Cancer Market

29.1. Africa HER2-Positive Breast Cancer Market Overview
29.2. Africa HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. HER2-Positive Breast Cancer Market Competitive Landscape And Company Profiles

30.1. HER2-Positive Breast Cancer Market Competitive Landscape
30.2. HER2-Positive Breast Cancer Market Company Profiles
- 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. HER2-Positive Breast Cancer Market Other Major And Innovative Companies

31.1. AstraZeneca plc
31.2. Novartis International AG
31.3. GlaxoSmithKline plc
31.4. Eli Lilly and Company
31.5. Amgen Inc.
31.6. Boehringer Ingelheim GmbH
31.7. Daiichi Sankyo Co. Ltd.
31.8. Incyte Corporation
31.9. BioNTech SE
31.10. MacroGenics Inc.
31.11. CStone Pharmaceuticals Co. Ltd.
31.12. Sorrento Therapeutics Inc.
31.13. Syndax Pharmaceuticals Inc.
31.14. Fate Therapeutics Inc.
31.15. Ambrx Biopharma Inc.

32. Global HER2-Positive Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The HER2-Positive Breast Cancer Market

34. Recent Developments In The HER2-Positive Breast Cancer Market

35. HER2-Positive Breast Cancer Market High Potential Countries, Segments and Strategies

35.1 HER2-Positive Breast Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 HER2-Positive Breast Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 HER2-Positive Breast Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer